Overview

A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.

Status:
Completed

Trial end date:
2017-04-21

Target enrollment:

Participant gender:

Summary

The purpose of this double-blind, placebo-controlled, comparative study and open-label extension study is to confirm the efficacy and safety of E2020 in subjects with Down syndrome having regression symptoms and disabled activities of daily living.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Donepezil